Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00784303 | Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology | completed | Phase 2 | 117 | Eisai Inc.INDUSTRY | 6 | Apr 22, 2020 | clinicaltrials |
| NCT03211117 | Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04319471 | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 70 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2020 | clinicaltrials |
| NCT01044433 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04296747 | Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer | unknown | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02569788 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02801487 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 6 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03923842 | Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours(Dern) | unknown | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | completed | Phase 2 | 66 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04222543 | Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging(PIVOT) | unknown | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04220528 | Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC | unknown | Phase 2 | 129 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02390739 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 16, 2019 | clinicaltrials |
| NCT03389295 | Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 118 | Xiayun He, MDOTHER | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01312350 | Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) | completed | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01013597 | Trial of LBH589 in Metastatic Thyroid Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02084732 | Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study | completed | Phase 2 | 35 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | terminated | Phase 2 | 34 | Eisai Inc.INDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT01230476 | Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma | terminated | Phase 2 | 3 | University of MalayaOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02794077 | Cyclophosphamide for Nasopharyngeal Carcinoma | completed | Phase 2 | 56 | The University of Hong KongOTHER | 0 | Oct 2, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
| NCT02849314 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02849327 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03007836 | High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02789189 | Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail | terminated | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Sep 6, 2019 | clinicaltrials |
| NCT03020329 | Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01309633 | Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 80 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT04015661 | Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC | unknown | Phase 2 | 92 | Fuzhou General HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT02390934 | Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer(RAD-THYR) | completed | Phase 2 | 13 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03932266 | Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma | unknown | Phase 2 | 73 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03890185 | Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC | unknown | Phase 2 | 108 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT02472080 | Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study(THYGEMOX) | terminated | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT00603915 | A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer | completed | Phase 2 | 20 | University Health Network, TorontoOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT03839602 | Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients | completed | Phase 2 | 103 | Sun Yat-sen UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03283293 | Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT | completed | Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00484601 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT00318890 | Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 48 | University of Alabama at BirminghamOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT01392235 | Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 58 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01621880 | Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma(BRAIN) | completed | Phase 2 | 112 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Apr 22, 2020source: clinicaltrials